tiprankstipranks
Trending News
More News >
Scholar Rock Holding Corp (SRRK)
NASDAQ:SRRK
Advertisement

Scholar Rock Holding (SRRK) AI Stock Analysis

Compare
466 Followers

Top Page

SRRK

Scholar Rock Holding

(NASDAQ:SRRK)

Rating:50Neutral
Price Target:
Scholar Rock's overall stock score reflects significant challenges due to financial underperformance, including a lack of revenue and ongoing losses. Despite these issues, positive strides in its SMA program and strategic leadership changes indicate potential for future growth. Mixed technical indicators and a weak valuation further moderate the outlook.
Positive Factors
Commercial Readiness
Management expressed confidence in its ability to support immediate launch following approval, ensuring regulatory alignment with its CDMO partners and external quality experts.
Pipeline Expansion
There is potential for expansion into other neuromuscular disorders and obesity through partnerships, highlighting the versatility of Scholar Rock's pipeline.
Regulatory Progress
The analyst expects apitegromab to be approved for a broad label in SMA, covering all types regardless of ambulatory status, due to positive Phase 3 data and safety profile.
Negative Factors
Operational Challenges
CMC inspections have identified insufficiencies at two CDMOs (one being Catalent).
Regulatory Delays
There is a potential delay in the PDUFA decision due to procedural observations from a recent FDA site inspection, which could impact the approval timeline.
Research Integrity
Investors should be aware of potential conflicts of interest in research reports involving Scholar Rock Holding.

Scholar Rock Holding (SRRK) vs. SPDR S&P 500 ETF (SPY)

Scholar Rock Holding Business Overview & Revenue Model

Company DescriptionScholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
How the Company Makes MoneyScholar Rock makes money primarily through the development and commercialization of its proprietary drug candidates. The company's revenue model includes partnerships and collaborations with larger pharmaceutical companies, which provide upfront payments, milestone payments, and royalties on future sales of successfully developed drugs. Additionally, Scholar Rock may generate income through licensing agreements, where it grants other companies the rights to develop and market its therapeutic candidates. The company's financial performance is heavily influenced by the progress of its clinical trials, regulatory approvals, and the successful commercialization of its products.

Scholar Rock Holding Earnings Call Summary

Earnings Call Date:Aug 06, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 17, 2025
Earnings Call Sentiment Positive
The call presents a predominantly positive outlook with significant regulatory and commercial progress for apitegromab, supported by strong financials and positive clinical trial results. However, there are challenges due to FDA observations at CDMO sites. While these issues pose potential risks, the company's preparedness and strategic initiatives provide confidence in overcoming these hurdles.
Q2-2025 Updates
Positive Updates
Regulatory and Commercial Progress for Apitegromab
The BLA for apitegromab has been accepted under priority review with a target action date of September 22. The company is preparing for a U.S. launch for SMA (spinal muscular atrophy) treatment and anticipates a European launch, starting with Germany in 2026.
Positive Clinical Trial Results
The SAPPHIRE trial showed statistically significant improvement in motor function for SMA patients treated with apitegromab. The EMBRAZE study met its primary endpoint, showing that apitegromab increased lean mass preservation by over 54% compared to tirzepatide alone.
Financial Stability and Strategic Investments
The company ended the quarter with $295 million. An additional $50 million is available under a debt facility, with a projected financial runway into 2027. The company is strategically investing in commercial readiness and pipeline expansion.
Global Launch Preparedness
Scholar Rock has fully staffed and deployed a U.S. customer-facing team to engage with SMA treatment centers, key opinion leaders, and payers. The company plans to reach patients globally, with an emphasis on targeting the unmet need for treatments that address muscle degeneration in SMA.
Negative Updates
CDMO Observations by FDA
FDA inspections resulted in observations at two contract development and manufacturing organization (CDMO) sites, including Catalent, Indiana. These observations require responses and could potentially impact the review process for apitegromab.
Company Guidance
During the Scholar Rock Second Quarter 2025 Business Update Conference Call, the company provided extensive guidance on its strategic priorities and anticipated milestones. Scholar Rock is gearing up for the U.S. commercial launch of apitegromab for SMA, with a target action date of September 22, 2025, following its acceptance under priority review by the FDA. The company also plans a series of country launches, starting in Europe with Germany in 2026. Scholar Rock aims to expand apitegromab into additional rare neuromuscular diseases and invest in R&D with the initiation of the Phase II OPAL Trial for infants and clinical development in other neuromuscular indications by the end of 2025. Financially, Scholar Rock ended Q2 with $295 million, expecting additional funding from warrants and debt facilities, which extends their runway into 2027. The company is committed to disciplined capital allocation to support its commercial and development initiatives, anticipating monetizing its priority review voucher post-approval.

Scholar Rock Holding Financial Statement Overview

Summary
Scholar Rock Holding faces significant financial challenges with no revenue and ongoing net losses. Despite a stable balance sheet with strong liquidity and low leverage, negative cash flows indicate reliance on external financing. Critical focus is needed on revenue generation and cost management to improve future profitability.
Income Statement
25
Negative
Scholar Rock Holding has shown no revenue for 2023 and 2024, indicating an absence of sales or other income-generating activities. The company is operating at a loss, with a significantly negative net income. Gross profit is also at zero, and the company has declining EBIT and EBITDA margins due to increasing expenses relative to revenues. The lack of revenue growth is concerning for future profitability.
Balance Sheet
45
Neutral
Scholar Rock Holding maintains a moderate equity base relative to its total assets, with an equity ratio around 77.6% in 2024. The debt-to-equity ratio is low at 0.18, suggesting conservative leverage. However, the company is incurring losses, which could impact future equity levels. Positive cash and cash equivalents indicate good liquidity.
Cash Flow
40
Negative
The company experiences negative operating cash flow, which raises concerns about its ability to sustain operations without external financing. Free cash flow is also negative, indicating that the company is not generating cash from its core operations. However, financing activities have provided substantial cash inflows, helping to mitigate cash flow deficiencies.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.0033.19M18.82M15.40M
Gross Profit-812.00K0.00-2.84M23.31M9.79M-58.66M
EBITDA-318.79M-237.52M-168.45M-131.38M-127.29M-85.39M
Net Income-315.69M-246.29M-165.79M-131.65M-131.80M-84.99M
Balance Sheet
Total Assets340.05M474.92M311.04M358.17M304.44M388.31M
Cash, Cash Equivalents and Short-Term Investments295.01M437.28M279.94M315.36M252.99M341.03M
Total Debt61.53M65.13M61.82M69.40M77.06M57.14M
Total Liabilities106.75M106.29M85.82M97.93M132.37M127.53M
Stockholders Equity233.29M368.63M225.22M260.24M172.07M260.77M
Cash Flow
Free Cash Flow-258.12M-201.05M-145.30M-133.76M-132.04M-64.36M
Operating Cash Flow-257.58M-200.95M-145.23M-132.69M-126.79M-60.27M
Investing Cash Flow-40.04M-76.06M41.14M-171.70M134.31M-63.50M
Financing Cash Flow357.18M353.03M102.57M194.83M44.95M247.82M

Scholar Rock Holding Technical Analysis

Technical Analysis Sentiment
Positive
Last Price32.44
Price Trends
50DMA
35.65
Negative
100DMA
33.55
Positive
200DMA
35.66
Negative
Market Momentum
MACD
-0.50
Negative
RSI
51.02
Neutral
STOCH
54.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRRK, the sentiment is Positive. The current price of 32.44 is below the 20-day moving average (MA) of 32.92, below the 50-day MA of 35.65, and below the 200-day MA of 35.66, indicating a neutral trend. The MACD of -0.50 indicates Negative momentum. The RSI at 51.02 is Neutral, neither overbought nor oversold. The STOCH value of 54.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SRRK.

Scholar Rock Holding Risk Analysis

Scholar Rock Holding disclosed 70 risk factors in its most recent earnings report. Scholar Rock Holding reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Scholar Rock Holding Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
$4.33B19.3333.18%14.41%627.78%
58
Neutral
$3.56B-108.49%20.02%33.45%
53
Neutral
$3.09B-19.99%-63.73%
52
Neutral
$3.14B-36.94%-9.10%
51
Neutral
$7.91B-0.36-41.70%2.23%23.45%-1.86%
50
Neutral
$3.18B-172.08%-29.50%
45
Neutral
$2.63B-77.58%-48.38%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SRRK
Scholar Rock Holding
32.44
24.41
303.99%
ACAD
ACADIA Pharmaceuticals
25.50
9.43
58.68%
VKTX
Viking Therapeutics
26.53
-27.60
-50.99%
APLS
Apellis Pharmaceuticals
28.65
-12.40
-30.21%
CRNX
Crinetics Pharmaceuticals
34.25
-16.14
-32.03%
IMVT
Immunovant
16.12
-17.91
-52.63%

Scholar Rock Holding Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Scholar Rock Appoints David Hallal as New CEO
Positive
Apr 28, 2025

Scholar Rock announced a significant management transition effective April 27, 2025, with David Hallal appointed as the new Chief Executive Officer, succeeding Dr. Jay Backstrom, who will become a Senior Advisor until October 31, 2025. This transition is part of a strategic move to prepare for the global launch of apitegromab, a promising treatment for spinal muscular atrophy (SMA), and includes the addition of three key executives: Akshay Vaishnaw as President of R&D, R. Keith Woods as Chief Operating Officer, and Vikas Sinha as Chief Financial Officer. These changes are expected to bolster Scholar Rock’s evolution into a fully integrated global commercial enterprise, enhancing its positioning in the biopharmaceutical industry and potentially benefiting stakeholders by accelerating the company’s growth and innovation efforts.

Spark’s Take on SRRK Stock

According to Spark, TipRanks’ AI Analyst, SRRK is a Neutral.

Scholar Rock Holding’s stock score is hindered by the lack of revenue and ongoing losses, despite a stable balance sheet and liquidity. While technical indicators provide mixed signals, the company’s strategic progress in its SMA program and forthcoming drug launch offer a positive outlook. However, valuation concerns remain due to significant net losses and no dividend yield. The overall score reflects these challenges, balanced by the potential long-term growth from its pipeline.

To see Spark’s full report on SRRK stock, click here.

Executive/Board ChangesShareholder Meetings
Scholar Rock Holding Appoints Interim Financial Officer
Neutral
Mar 21, 2025

Scholar Rock Holding Corporation announced the appointment of Erin Moore as interim Principal Financial Officer and interim Principal Accounting Officer, effective March 21, 2025, following the departure of Edward Myles. Moore, who has been with the company since 2018 and holds extensive financial and accounting credentials, will temporarily oversee financial operations. Additionally, the company scheduled its 2025 Annual Meeting of Stockholders for May 22, 2025, with March 26, 2025, set as the record date for stockholders entitled to vote. The deadline for stockholder proposals is March 31, 2025, adhering to the Securities Exchange Act regulations.

Product-Related AnnouncementsBusiness Operations and StrategyFinancial Disclosures
Scholar Rock Advances SMA Program with Apitegromab Submission
Positive
Feb 27, 2025

Scholar Rock reported its financial results for 2024, highlighting significant progress in its SMA program with the submission of a Biologics License Application for apitegromab, anticipated to launch in the U.S. in late 2025. The company also plans to expand its research into other neuromuscular disorders and cardiometabolic indications, supported by a strong financial position and recent public offering.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 29, 2025